Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute.
See the KPTV Health Watch news story about Providence Cancer Institute expansion on the 11th floor of Providence's Robert W. Franz Cancer Center.
Features Dr. Kevin Olson and infusion nurse Brittany O'Connell from Providence Cancer Institute in Portland, Oregon.
More than 10 studies of investigational and FDA-approved immunotherapies for people with advanced melanoma are currently open at Providence Cancer Institute.
A recent assessment of the first 170 throat-cancer patients treated with transoral robotic surgery followed by risk-adapted adjuvant therapy at Providence Cancer Institute offers compelling evidence in favor of this new treatment approach.
From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That’s why we’re expanding and consolidating outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.
Many clinical trials are open only to patients with metastatic disease. One of the translational research goals of the Providence Head and Neck Cancer Program is to bring immunotherapy into treatment earlier.
Anti-OX40, a novel immunotherapy engineered by researchers at Providence Cancer Institute, continues to show promise as a potentially powerful way to treat cancer.
Adoptive T-cell transfer therapy is emerging as one of the most effective treatments to date for people with advanced melanoma. Now this treatment is available to patients with advanced or recurrent head and neck cancers through a clinical trial at Providence Cancer Institute.
For breast cancer patients, choosing a breast cancer surgeon for care has important benefits. Learn more from Kristen Massimino, M.D., medical director of the Providence Breast Cancer Program.